{"id":"W4391430175","doi":"10.1172/jci176454","title":"HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; Knight Cancer Institute, Oregon Health and Science University; G1 Therapeutics; MacroGenics; Puma Biotechnology; Incyte; National Cancer Institute; Natera; Genomic Health; Daiichi Sankyo Europe; Sanofi; Oregon Health and Science University; Gilead Sciences; University of Texas Southwestern Medical Center; Amgen; Pfizer; Susan G. Komen for the Cure; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Trastuzumab; Medicine; Pertuzumab; Lapatinib; Oncology; Internal medicine; KRAS; Neoadjuvant therapy; ErbB; Cancer research; Cancer; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002606289,0.0005544574,0.001166079,0.0003475036,0.0003882592,0.0007145175,0.0003734991,0.0008721731,0.003401125],"category_scores_gemma":[0.001320557,0.0002152819,0.0004706036,0.0005502221,0.000446675,0.0006065394,0.0003683722,0.001124738,0.000549804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007895093,"about_ca_system_score_gemma":0.0009821553,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005808297,"about_ca_topic_score_gemma":0.002240609,"domain_scores_codex":[0.9990545,0.0004954649,0.000053843,0.0001296755,0.0001122731,0.0001542127],"domain_scores_gemma":[0.9994381,0.0001376197,0.0001635994,0.00005006183,0.00004573186,0.00016492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7685505,0.009054597,0.09110963,0.0005727508,0.001933231,0.0004551941,0.0002282747,0.003669955,0.04309681,0.000596424,0.01039567,0.07033695],"study_design_scores_gemma":[0.2740109,0.1986285,0.485866,0.00009437916,0.002406679,0.001119219,0.0002784371,0.005907751,0.01112601,0.002385098,0.01804962,0.0001274464],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915029,0.0009605085,0.0003197315,0.0004227751,0.00004226383,0.001023512,0.002975766,0.00004969491,0.002702776],"genre_scores_gemma":[0.9904528,0.0002211117,0.000543353,0.0005233995,0.00005975395,0.001619382,0.00484488,0.00002277361,0.001712582],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003401125,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2593482090986527,"score_gpt":0.5403783004386817,"score_spread":0.281030091340029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}